how many people are using glp-1 Products - Data Briefs - Number 537 GLP-1 trends 2025: real-world data,

[DOI] [PubMed] [Google Scholar] 93.Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW

After 52 weeks of once weekly Zepbound (10 or 15 mg) or placebo, participants on Lillys drug experienced a statistically significant and clinically meaningful reduction in apnea or hypopnea events

Most clinical studies evaluating Wegovy for weight loss used the 2.4mg weekly dose, which is why it is considered the target treatment level for many patients

Criminal counterfeiters and questionable suppliers are deliberately exploiting this trend by promoting these products sometimes very aggressively on social media, websites or via direct advertising in particular

PA potential solution for this challenge is to explore formulations offering less frequent injections andral formulations, which may provide a more viable long-term treatment solution